ArticleAmerican journal of hematology2026

Comparative Efficacy of Belantamab Mafodotin in Combination With Bortezomib and Dexamethasone Versus Standards of Care in Patients With Third-Line or Later Relapsed/Refractory Multiple Myeloma.

Joshua Richter et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.